WJPR Citation New

  All Since 2020
 Citation  8502  4519
 h-index  30  23
 i10-index  227  96

Login

Best Article Awards

World Journal of Pharmaceutical Research (WJPR) is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.
Best Paper Award :
Dr. Dhrubo Jyoti Sen
Download Article: Click Here

Search

Track Your Article

Abstract

LITERARY REVIEW ON CHIKITSA OF AMAVATA

Vd. Laxman C. Khajekar* and Vd. Omkar Kortikar

.

Abstract

Ayurvedic as Indian system of medicine is hope for various chronic Auto-immune diseases suffering humanity in today’s world. One of the commonest chronic inflammatory joint disease Amavata (Rheumatoid Arthritis). Rheumatoid Arthritis is a chronic multi-system Auto-Immune disease, RA show signs like swelling, pain and stiffness of joints. Chronic condition may cause debility, deformed joints and crippling. Unfortunately, there is no permanent cure for this disease. Ayurveda can play a Vital role in treatment of Amavata. So, need to study Ayurveda classics with deep understanding is demand of today. Amavata is derived from word “Ama” and “Vata”. The Ama along with Tridosha occupies Shleshmasthana and results in Amavata. Brihatrayi Acharyas Charak, Sushruta and Vagbhat had widely mentioned about Ama and Avritta Vata. First time, Madhavkar mentioned Amavata as separate disease. After that Vangsena, Chakradutta, Bhaishajyaratnavali has elaborated the various treatment modalities of Amavata. Here, the main objectives are to introduce Amavata as a disease by detailing of its Ayurvedic Management.

Keywords: Amavata, Rheumatoid Arthritis, Ama, Vata, Chikitsa.


[Full Text Article]  [Download Certificate]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More